| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $5,335,994 ) |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | F30AG085984 | The Role of TMEM106B in FTLD-TDP Pathogenesis | 000 | 3 | NIH | 1/16/2026 | $49,738 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG077771 | Nuclear import receptors as modifiers of TDP-43 phase transition and toxicity in FTD/ALS | 000 | 4 | NIH | 12/15/2025 | $638,607 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG079859 | Therapeutic evaluation of targeting Tau Tubulin kinase-1 in Alzheimer’s disease | 000 | 4 | NIH | 12/24/2025 | $492,975 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | F31NS141239 | Role of meningeal lymphatic drainage in CSF1R-related leukoencephalopathy | 001 | 1 | NIH | 1/15/2026 | $0 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | F31NS141239 | Role of meningeal lymphatic drainage in CSF1R-related leukoencephalopathy | 000 | 1 | NIH | 1/15/2026 | $49,538 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG075802 | Investigating regional and cellular vulnerabilities to tau pathology in young-onset Alzheimer's disease | 000 | 5 | NIH | 12/18/2025 | $2,695,731 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R35NS137447 | Expanding insights into FTD disease mechanisms | 000 | 2 | NIH | 12/17/2025 | $1,024,684 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R21CA296671 | ECT2 Isoform Switch in Pancreatic Cancer. | 000 | 2 | NIH | 12/16/2025 | $164,619 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R21CA288808 | Epigenetic Regulation of T Cell Metabolism and Immune Functions by Sirt6 | 000 | 2 | NIH | 12/30/2025 | $164,619 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01CA295558 | Generating Synthetic Lethality in Glioblastoma with a First-In-Class Non-Muscle Myosin II Inhibitor | 000 | 2 | NIH | 12/18/2025 | $539,735 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01CA262393 | Targeted Prevention of Postpartum-Related Breast Cancer (PRBC) | 000 | 5 | NIH | 1/16/2026 | $380,600 |
| | 2026 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01CA258274 | Engineering tissue inhibitor of metalloproteinases-2 (TIMP-2) for triple negative breast cancer therapy | 000 | 5 | NIH | 1/6/2026 | $0 |
| | 2026 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | K24AG053435 | Neuropathological changes underlying clinical heterogeneity in Alzheimer dise | 001 | 11 | NIH | 2/12/2026 | $140,341 |
| | 2026 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | U19AG069701 | Biology and pathobiology of apoE in aging and Alzheimer's disease | 000 | 5 | NIH | 12/11/2025 | $0 |
| | 2026 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R21CA279916 | Deiminated molecules as markers for developing pancreatic cancer - A1 | 000 | 2 | NIH | 10/21/2025 | $0 |
| | 2026 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01NS121125 | Frontotemporal dementia and related disorders: transcriptomic profiling, biomarker discovery, and mechanistic insight | 000 | 5 | NIH | 1/7/2026 | $0 |
| | 2026 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01GM144393 | Exploiting new approaches for selective inhibition of trypsins | 000 | 4 | NIH | 10/27/2025 | $0 |
| | 2026 | 2024 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG065219 | Impact of T cells on the CNS during aging and Alzheimer’s disease | 002 | 5 | NIH | 2/11/2026 | $0 |
| | 2026 | 2024 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG065219 | Impact of T cells on the CNS during aging and Alzheimer’s disease | 000 | 5 | NIH | 1/27/2026 | -$485,149 |
| | 2026 | 2024 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01HG011461 | PaSAGE: PAtient Supported Approaches to Gene Editing | 000 | 3 | NIH | 1/7/2026 | -$403,379 |
| | 2026 | 2024 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01HG013718 | Supporting Just-in-Time Consent for Prenatal Screening | 000 | 1 | NIH | 2/12/2026 | $0 |
| | 2026 | 2024 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01CA237602 | Involution-based biomarkers of breast cancer risk | 000 | 5 | NIH | 11/21/2025 | -$36,497 |
| | 2026 | 2023 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01NS110085 | Mitochondrial Sirtuin 3 in Parkinson's disease | 000 | 5 | NIH | 1/30/2026 | -$12,569 |
| | 2026 | 2023 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01NS110085 | Mitochondrial Sirtuin 3 in Parkinson's disease | 000 | 5 | NIH | 1/30/2026 | -$3,384 |
| | 2026 | 2023 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01CA233790 | Therapeutic implication of CD38 in CLL | 000 | 5 | NIH | 1/14/2026 | -$64,216 |
| | 2026 | 2023 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01CA229560 | Role of ICAM1 in development and progression of pancreatic cancer | 000 | 5 | NIH | 1/14/2026 | $0 |
| | 2026 | 2022 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | RF1AG076122 | Capturing the molecular complexity of tau pathology-associated proteomes involved in the etiology of Alzheimer's disease and related dementias | 000 | 1 | NIH | 1/23/2026 | -$304,220 |
| | 2026 | 2022 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | RF1AG076122 | Capturing the molecular complexity of tau pathology-associated proteomes involved in the etiology of Alzheimer's disease and related dementias | 000 | 1 | NIH | 1/23/2026 | $304,220 |
|
| Issue Date FY: 2025 ( Subtotal = $53,918,576 ) (Continued on the next page) |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | U19AG069701 | Biology and pathobiology of apoE in aging and Alzheimer's disease | 000 | 5 | NIH | 6/18/2025 | $6,293,390 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG072719 | Assessment of a novel tau propagation pathway from layer II medial entorhinal cortical neurons to CA1 pyramidal neurons as an early Braak stage mouse model | 001 | 5 | NIH | 6/13/2025 | $42,632 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG072719 | Assessment of a novel tau propagation pathway from layer II medial entorhinal cortical neurons to CA1 pyramidal neurons as an early Braak stage mouse model | 000 | 5 | NIH | 4/3/2025 | $479,602 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01CA258274 | Engineering tissue inhibitor of metalloproteinases-2 (TIMP-2) for triple negative breast cancer therapy | 002 | 5 | NIH | 9/16/2025 | $32,250 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01CA258274 | Engineering tissue inhibitor of metalloproteinases-2 (TIMP-2) for triple negative breast cancer therapy | 001 | 5 | NIH | 2/14/2025 | $0 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01CA258274 | Engineering tissue inhibitor of metalloproteinases-2 (TIMP-2) for triple negative breast cancer therapy | 000 | 5 | NIH | 1/22/2025 | $290,242 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG067763 | Molecular characterization of extracellular vesicles for the spread of misfolded tau protein | 001 | 5 | NIH | 6/13/2025 | $48,912 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG067763 | Molecular characterization of extracellular vesicles for the spread of misfolded tau protein | 000 | 5 | NIH | 4/4/2025 | $550,252 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01NS117461 | Poly(ADP-ribose) promotes the condensation and toxicity of C9orf72 arginine-rich dipeptide repeat proteins | 000 | 4 | NIH | 7/11/2025 | $480,550 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01NS117461 | Poly(ADP-ribose) promotes the condensation and toxicity of C9orf72 arginine-rich dipeptide repeat proteins | 000 | 4 | NIH | 7/11/2025 | $101,935 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | U01NS119169 | Long-Term Observational Extension of Participants in the CREST-2 Randomized Clinical Trial | 001 | 5 | NIH | 9/12/2025 | $740,873 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01DK139207 | Deciphering Pancreatitis Microenvironment through Intravital Imaging | 000 | 2 | NIH | 4/16/2025 | $578,659 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | U01NS080168 | Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial (CREST-2) | 002 | 12 | NIH | 9/22/2025 | $156,497 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | U01NS080168 | Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial (CREST-2) | 001 | 12 | NIH | 8/26/2025 | $302,827 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R37CA248298 | Role of Sirt2 in T Cell Metabolism | 002 | 6 | NIH | 9/10/2025 | $35,800 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R37CA248298 | Role of Sirt2 in T Cell Metabolism | 001 | 6 | NIH | 2/14/2025 | $322,194 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01CA295558 | Generating Synthetic Lethality in Glioblastoma with a First-In-Class Non-Muscle Myosin II Inhibitor | 000 | 1 | NIH | 12/25/2024 | $607,634 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG076537 | Extracellular vesicle-based senotherapeutics for aging diabetic kidneydisease | 000 | 3 | NIH | 3/24/2025 | $521,046 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG076537 | Extracellular vesicle-based senotherapeutics for aging diabetic kidneydisease | 001 | 3 | NIH | 8/29/2025 | $46,318 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R21CA288808 | Epigenetic Regulation of T Cell Metabolism and Immune Functions by Sirt6 | 000 | 1 | NIH | 12/18/2024 | $219,491 |
|
